Literature DB >> 30051232

Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.

Leigh Anne Keough1, Amy Krauss2, Joanna Q Hudson3,4.   

Abstract

Background Patients requiring SLED are often critically ill and/or hemodynamically unstable, and often need antibiotic therapy for life-threatening infections. Antibiotic dosing recommendations for intermittent hemodialysis and continuous renal replacement therapy are not appropriate for SLED and there is substantial concern for under dosing. Objective To characterize the adequacy of antibiotic dosing during SLED. Setting: Inpatient adult acute care hospital. Methods A retrospective chart review was performed for the period of October 2010 to August 2013 to identify patients who received SLED and at least one of the selected antibiotics: cefepime, daptomycin, piperacillin/tazobactam, meropenem, and vancomycin. Dosing regimens were evaluated each day the patient was receiving one of these antibiotics concurrently with SLED. The administered antibiotic dosing regimens were defined as "adequate" or "inadequate" based on recommendations available in the literature. Main outcome measure The percentage of adequate antibiotic days for each antibiotic. Results Antibiotic regimens were evaluated for a total of 51 patients: 35 (69%) with acute kidney injury, 16 (31%) with end-stage renal disease, mean SLED duration 9.3 ± 1.7 h. The total percent of adequate antibiotic days were: vancomycin 86%, cefepime 62%, daptomycin 58%, meropenem 35%, and piperacillin/tazobactam 20%. Under dosing accounted for 63% of the days antibiotic dosing was considered inadequate.
Conclusion: Antibiotic dosing was frequently inadequate, especially for antibiotics requiring more frequent dosing, suggesting a high potential for subtherapeutic levels during the majority of time critically ill patients are requiring SLED.

Entities:  

Keywords:  Antibiotics; Dialysis; Drug removal; Kidney disease; Sustained low-efficiency dialysis; United States

Mesh:

Substances:

Year:  2018        PMID: 30051232     DOI: 10.1007/s11096-018-0697-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  19 in total

1.  Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.

Authors:  Susan J Lewis; Michael B Kays; Bruce A Mueller
Journal:  J Clin Pharmacol       Date:  2016-04-08       Impact factor: 3.126

Review 2.  Antibiotic Dosing in Continuous Renal Replacement Therapy.

Authors:  Alexander R Shaw; Bruce A Mueller
Journal:  Adv Chronic Kidney Dis       Date:  2017-07       Impact factor: 3.620

3.  Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy.

Authors:  M R Marshall; T A Golper; M J Shaver; M G Alam; D K Chatoth
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

4.  Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Gary R Matzke; George R Aronoff; Arthur J Atkinson; William M Bennett; Brian S Decker; Kai-Uwe Eckardt; Thomas Golper; Darren W Grabe; Bertram Kasiske; Frieder Keller; Jan T Kielstein; Ravindra Mehta; Bruce A Mueller; Deborah A Pasko; Franz Schaefer; Domenic A Sica; Lesley A Inker; Jason G Umans; Patrick Murray
Journal:  Kidney Int       Date:  2011-09-14       Impact factor: 10.612

Review 5.  Effect of sustained low efficient dialysis versus continuous renal replacement therapy on renal recovery after acute kidney injury in the intensive care unit: A systematic review and meta-analysis.

Authors:  Bernadett Kovacs; Katrina J Sullivan; Swapnil Hiremath; Rakesh V Patel
Journal:  Nephrology (Carlton)       Date:  2017-05       Impact factor: 2.506

6.  Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis.

Authors:  Jian P Mei; Azadeh Ali-Moghaddam; Bruce A Mueller
Journal:  Int J Clin Pharm       Date:  2016-02

7.  Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy.

Authors:  Bridget A Scoville; Bruce A Mueller
Journal:  Am J Kidney Dis       Date:  2012-11-03       Impact factor: 8.860

8.  Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.

Authors:  Katherine N Gharibian; Bruce A Mueller
Journal:  Clin Nephrol       Date:  2016-07       Impact factor: 0.975

9.  Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: opportunities for pharmacists.

Authors:  Laura E Harris; Anne B Reaves; Amy G Krauss; Justin Griner; Joanna Q Hudson
Journal:  Int J Pharm Pract       Date:  2012-07-09

10.  Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.

Authors:  Stephan Braune; Christina König; Jason A Roberts; Axel Nierhaus; Oliver Steinmetz; Michael Baehr; Stefan Kluge; Claudia Langebrake
Journal:  Crit Care       Date:  2018-01-30       Impact factor: 9.097

View more
  3 in total

1.  Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients.

Authors:  Uwe Liebchen; Marian Klose; Michael Paal; Michael Vogeser; Michael Zoller; Ines Schroeder; Lisa Schmitt; Wilhelm Huisinga; Robin Michelet; Johannes Zander; Christina Scharf; Ferdinand A Weinelt; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2021-04-20

2.  Vancomycin for Dialytic Therapy in Critically Ill Patients: Analysis of Its Reduction and the Factors Associated with Subtherapeutic Concentrations.

Authors:  Fernanda Moreira de Freitas; Welder Zamoner; Pamela Falbo Dos Reis; André Luís Balbi; Daniela Ponce
Journal:  Int J Environ Res Public Health       Date:  2020-09-19       Impact factor: 3.390

3.  The landscape of renal replacement therapy in Veterans Affairs Medical Center intensive care units.

Authors:  Chandan Vangala; Maulin Shah; Natasha N Dave; Layth Al Attar; Sankar D Navaneethan; Venkat Ramanathan; Susan Crowley; Wolfgang C Winkelmayer
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.